John P. Butler serves as the President and Chief Executive Officer at Akebia Therapeutics Inc., a biopharmaceutical company focused on developing innovative therapies for people with kidney disease. With a robust background in the biopharmaceutical industry, Butler has been instrumental in steering Akebia towards its mission of improving the lives of patients suffering from kidney-related conditions. He joined Akebia in 2013 and has since played a pivotal role in the company's growth and development, particularly in advancing its lead product candidate, vadadustat, through clinical trials. Before his tenure at Akebia, Butler held various leadership positions at other notable biopharmaceutical companies. He was the Chief Business Officer at Amag Pharmaceuticals, where he was responsible for strategic planning and business development. Prior to that, he served as Senior Vice President of Business Development at Synta Pharmaceuticals, where he contributed to the company's efforts in oncology drug development. Butler's extensive experience in strategic planning, business development, and clinical development has been crucial in his role at Akebia, where he has successfully led the company through several key milestones, including the completion of Phase 3 clinical trials for vadadustat and the submission of a New Drug Application to the FDA. Under Butler's leadership, Akebia has not only advanced its clinical pipeline but also expanded its global presence. His strategic vision has enabled the company to forge important partnerships and collaborations, enhancing its capabilities in drug development and commercialization. Butler's commitment to innovation and patient care continues to drive Akebia's efforts to bring new treatment options to the kidney disease community, solidifying his reputation as a respected leader in the biopharmaceutical industry.